Genentech reveals updates from Phase 3 IMagyn050 clinical trial
Category: #health  By Saipriya Iyer  Date: 2020-07-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech reveals updates from Phase 3 IMagyn050 clinical trial

Genentech has recently announced that its Phase III IMagyn050 study did not meet the primary endpoint of PFS (progression-free survival).

In the study, the company added the Tecentriq ® (atezolizumab) to the Avastin® (bevacizumab), paclitaxel, & carboplatin to develop a front-line treatment for women who are diagnosed with advanced-stage ovarian cancer. The topline results indicate that the safety on the combination of Tecentriq with Avastin, paclitaxel, & carboplatin was reportedly consistent with the combination’s known safety profile.

According to Global Product Development’s head and chief medical officer, Dr. Levi Garraway, ovarian cancer is considered as an aggressive type of cancer, which poses high difficulty for treatment in advanced stages. Despite the unfavorable results from the recent study, the company will remain committed to advancing the treatments of women with the disease. Avastin will pose as the key component for use in the treatment of the front-line ovarian cancer among women.

Data for the OS (overall survival) co-primary endpoint are not mature currently and follow-up will continuously take place until the planned analysis in the future. In order to inform the public of the Tecentriq gynecological development program, results from the recent Phase 3 trial will be evaluated further. This program for the treatment of these patients has been developed by combining Tecentriq with Avastin. This has helped the patients with the newly diagnosed, relapsed, or advanced ovarian & cervical cancers live without further advancement of the disease, and has been demonstrated in results across 7 pivotal Phase 3 studies. The trials have registered more than 5,000 women.

Genentech has maintained an extensive Tecentriq development program. There are multiple ongoing as well as planned Phase 3 studies conducted across the neck, head, gynecological, gastrointestinal, breast, skin, genitourinary, and lung cancers. To treat these patients, the studies evaluate Tecentriq or in combination with other available medicines.

Source credit:

https://www.gene.com/media/press-releases/14862/2020-07-12/genentech-provides-update-on-phase-iii-s



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...

Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
Reliance Retail sells 1.75% stake for $1.02 billion to Silver Lake
By Saipriya Iyer

Reliance Industries Ltd., an Indian conglomerate, has reportedly raised Rs.7,500 crore (Dollar 1.02 billion) by selling a stake in its retail unit to Silver Lake Partners, a private equity firm.

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials

CNBG, Sinovac to enroll foreign patients in COVID-19 vaccine trials
By Saipriya Iyer

The Chinese pharmaceutical firms are planning to enroll 50,000 candidates from different countries in the Phase 3 trials of COVID-19 vaccine

China National Biotec G...